#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	15762	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2009	778.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1388	1388	C	902	C,T	813,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28652	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3421	833.6	0	.	n	.	0	T695C	SNP	695	695	T	911	911	C	833	C,A	751,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28652	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3421	833.6	0	.	n	.	0	A1638G	SNP	1638	1638	A	1854	1854	G	895	G,A	601,214	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28652	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3421	833.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2187	2187	C	964	C	866	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28652	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3421	833.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2261	2261	A	962	A	856	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28652	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3421	833.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2813	2813	C	876	C	801	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	1988	folP	855	855	100.0	folP.l15.c30.ctg.1	1485	133.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1016	1018	AGC	184;184;183	A;G;C	170;169;167	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5952	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3332	178.2	1	SNP	p	S91F	1	.	.	271	273	TTC	565	567	TTC	228;229;229	T;T;C,A	204;205;202,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5952	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3332	178.2	1	SNP	p	D95G	1	.	.	283	285	GGC	577	579	GGC	224;222;222	G;G;C	197;196;192	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5952	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3332	178.2	1	SNP	p	G95N	0	.	.	283	285	GGC	577	579	GGC	224;222;222	G;G;C	197;196;192	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1648	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1390	118.2	1	SNP	p	G45D	0	.	.	133	135	GGC	535	537	GGC	214;212;211	G;G;C,CT	193;193;200,1	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	888	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	950	93.0	0	.	n	.	0	A197.	DEL	197	197	A	537	537	A	244	A	219	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6216	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2914	212.7	1	SNP	p	D86N	0	.	.	256	258	GAC	598	600	GAC	248;245;245	G,A;A;C	226,1;224;227	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6216	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2914	212.7	1	SNP	p	R87I	0	.	.	259	261	CGT	601	603	CGT	245;244;246	C,T;G;T	227,1;226;226	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6216	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2914	212.7	1	SNP	p	R87W	0	.	.	259	261	CGT	601	603	CGT	245;244;246	C,T;G;T	227,1;226;226	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6216	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2914	212.7	1	SNP	p	S87R	1	.	.	259	261	CGT	601	603	CGT	245;244;246	C,T;G;T	227,1;226;226	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6216	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2914	212.7	1	SNP	p	S88P	0	.	.	262	264	TCC	604	606	TCC	246;246;247	T;C;C	230;230;229	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4522	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2518	178.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1454	1456	GGC	179;178;176	G;G;C	164;166;158	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	4376	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2267	192.0	1	SNP	p	A311V	0	.	.	931	933	GCC	1153	1155	GCC	250;246;245	G;C;C	230;229;229	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4376	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2267	192.0	1	SNP	p	I312M	1	.	.	934	936	ATG	1156	1158	ATG	248;247;248	A;T;G	230;228;230	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4376	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2267	192.0	1	SNP	p	V316T	1	.	.	946	948	ACC	1168	1170	ACC	245;245;245	A;C;C	228;229;228	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4376	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2267	192.0	1	SNP	p	T316P	0	.	.	946	948	ACC	1168	1170	ACC	245;245;245	A;C;C	228;229;228	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4376	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2267	192.0	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1669	1671	ACC	237;238;240	A;C;C	209;215;216	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4376	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2267	192.0	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1723	1725	GCG	232;230;226	G;C;G	209;208;204	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4376	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2267	192.0	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1723	1725	GCG	232;230;226	G;C;G	209;208;204	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4376	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2267	192.0	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1846	1848	GGT	202;204;205	G;G;T	177;175;176	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4376	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2267	192.0	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1855	1857	AGC	201;201;200	A;G;C	170;169;168	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4376	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2267	192.0	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1873	1875	CCG	180;182;179	C,G;C;G,C	128,8;129;128,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6100	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3218	189.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1714	1716	CCG	213;214;215	C;C;G,A	187;190;187,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2308	porA	1146	1146	99.91	porA.l6.c17.ctg.1	1791	128.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	571	571	C	148	C	134	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3200	porB1b	1038	1038	99.9	porB1b.l15.c17.ctg.1	1525	208.3	0	.	p	.	0	G210R	NONSYN	628	630	GGA	972	974	AGA	286;278;278	A;G;A	263;256;257	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3200	porB1b	1038	1038	99.9	porB1b.l15.c17.ctg.1	1525	208.3	1	SNP	p	G120K	1	.	.	358	360	AAG	702	704	AAG	298;297;297	A;A;G	272;274;269	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3200	porB1b	1038	1038	99.9	porB1b.l15.c17.ctg.1	1525	208.3	1	SNP	p	N121D	0	.	.	361	363	AAC	705	707	AAC	296;296;300	A;A;C	271;270;273	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3200	porB1b	1038	1038	99.9	porB1b.l15.c17.ctg.1	1525	208.3	1	SNP	p	A121N	1	.	.	361	363	AAC	705	707	AAC	296;296;300	A;A;C	271;270;273	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11614	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4790	241.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1250	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1024	121.3	1	SNP	p	V57M	1	.	.	169	171	ATG	567	569	ATG	251;253;251	A;T;G	238;238;236	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
